TME Pharma N.V. (EPA:ALTME)
France · Delayed Price · Currency is EUR 0.0892
+0.0014 (1.59%)
Aug 21, 2026, 5:35 PM CET
TME Pharma Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Other Revenue | - | - | - | - | 0.03 |
| - | - | - | - | 0.03 | |
Revenue Growth | - | - | - | - | -5.71% |
Gross Profit | - | - | - | - | 0.03 |
Selling, General & Admin | 1.55 | 2.98 | 2.99 | 3.88 | 2.88 |
Research & Development | 1.36 | 2.3 | 2.65 | 8.15 | 10.66 |
Other Operating Expenses | -0.05 | -0.02 | -0.02 | -0.02 | -0.04 |
Operating Expenses | 2.86 | 5.26 | 5.62 | 12.01 | 13.49 |
Operating Income | -2.86 | -5.26 | -5.62 | -12.01 | -13.46 |
Interest Expense | -0.03 | -0.02 | -0.02 | -0.13 | -0.05 |
Currency Exchange Gain (Loss) | -0 | 0.01 | 0.01 | -0.03 | 0.18 |
Other Non Operating Income (Expenses) | -0.39 | -0.45 | -1.34 | -3.27 | -1.42 |
EBT Excluding Unusual Items | -3.29 | -5.72 | -6.97 | -15.45 | -14.74 |
Other Unusual Items | - | - | 0.24 | 0.32 | 0.29 |
Pretax Income | -3.29 | -5.72 | -6.73 | -15.13 | -14.45 |
Income Tax Expense | - | - | 0 | 0.01 | 0 |
Earnings From Continuing Operations | -3.29 | -5.72 | -6.74 | -15.13 | -14.45 |
Minority Interest in Earnings | - | - | - | 0 | 0 |
Net Income | -3.29 | -5.72 | -6.74 | -15.13 | -14.45 |
Net Income to Common | -3.29 | -5.72 | -6.74 | -15.13 | -14.45 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 94 | 36 | 5 | 1 | 1 |
Shares Outstanding (Diluted) | 94 | 36 | 5 | 1 | 1 |
Shares Change | 161.66% | 616.96% | 326.62% | 78.28% | 103.92% |
EPS (Basic) | -0.03 | -0.16 | -1.34 | -12.86 | -21.90 |
EPS (Diluted) | -0.03 | -0.16 | -1.34 | -12.86 | -21.90 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -3.42 | -4.65 | -5.65 | -12.16 | -12.4 |
Free Cash Flow Per Share | -0.04 | -0.13 | -1.13 | -10.34 | -18.79 |
Gross Margin | - | - | - | - | 100.00% |
Operating Margin | - | - | - | - | -40790.91% |
Profit Margin | - | - | - | - | -43793.94% |
Free Cash Flow Margin | - | - | - | - | -37560.61% |
EBITDA | -2.84 | -5.24 | -5.59 | -11.99 | -13.44 |
D&A For EBITDA | 0.02 | 0.02 | 0.03 | 0.02 | 0.02 |
EBIT | -2.86 | -5.26 | -5.62 | -12.01 | -13.46 |